Interferon Gamma Release Assays (IGRA) Testing Versus Tuberculin Skin Test in Renal Transplant Recipients

Sponsor
Ligue Pulmonaire Genevoise (Other)
Overall Status
Completed
CT.gov ID
NCT01608685
Collaborator
(none)
205
1
23
8.9

Study Details

Study Description

Brief Summary

Interferon gamma release assays (IGRA) have been shown to be more specific and sensitive for the detection of tuberculosis (latent or active infection) than the tuberculin skin test (TST) in immunocompetent individuals. However, very little data are available concerning the relative performance of IGRA and TST in immunosuppressed individuals from other causes than HIV.

The investigators hypothesize that IGRAs would be more sensitive and specific than the TST in a group of renal transplant recipients under chronic immunosuppressive treatment for detecting latent tuberculosis infection.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    In a recent study (Triverio PA et al. "Interferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis in haemodialysis patients". Nephrol Dial Transplant 2009; 24: 1952-6), the investigators had compared 2 IGRAs (T-SPOT.TB and Quantiferon Gold) with the TST and shown that one IGRA was clearly more sensitive than the TST but that both tests had a very low sensitivity for detecting prior TB.

    This study applies the same protocol to renal transplant recipients undergoing routine annual check-up visits: questionnaire with detailed collection of risk factors for latent tuberculosis infection (LTBI), history of prior contact with tuberculosis (TB), BCG (Bacille of Calmette and Guerin vaccine), prior TB or LTBI, treatment for TB or LTBI, analysis of chest X-ray for signs of prior TB, on-going treatment, level of immunosuppression (CD4 lymphocytes), simultaneous blood sampling for T-SPOT.TB and Quantiferon Gold, and tuberculin skin testing.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    205 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Cross-Sectional
    Official Title:
    Interferon Gamma Release Assays Versus Tuberculin Skin Testing for the Detection of Latent Tuberculosis Infection in Renal Transplant Recipients
    Study Start Date :
    Jan 1, 2010
    Actual Primary Completion Date :
    Dec 1, 2011
    Actual Study Completion Date :
    Dec 1, 2011

    Arms and Interventions

    Arm Intervention/Treatment
    Renal transplant recipients

    Inclusion criteria: All renal transplant recipients followed by the Division of Nephrology aged above 18 years, and having accepted study protocol after informed consent

    Outcome Measures

    Primary Outcome Measures

    1. Agreement between results of QuantiFERON-Gold-in-tube and probability of latent tuberculosis infection [Up to 3 years]

      Agreement between probability of latent tuberculosis infection - established on the basis of a questionnaire and chest X-ray - and results of QuantiFERON-Gold-in-tube is computed

    2. Agreement between results of T-SPOT.TB and probability of latent tuberculosis infection [Up to 3 years]

      Agreement between probability of latent tuberculosis infection - established on the basis of a questionnaire and chest X-ray - and result of T-SPOT.TB is computed

    Secondary Outcome Measures

    1. Agreement between results of IGRA tests and TST in renal transplant recipients [Up to 3 years]

      Agreement between results of IGRA testing and between each IGRA test and TST will be determined by computing kappa values

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • prior renal transplantation;

    • age > 18;

    • stable clinical condition

    Exclusion Criteria:
    • hypersensitivity to tuberculin skin testing

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Geneva University Hospital/Division of Nephrology Geneva 11 Geneva Switzerland 1211

    Sponsors and Collaborators

    • Ligue Pulmonaire Genevoise

    Investigators

    • Principal Investigator: Karin Hadaya, MD, Division of Nephrology/Geneva University Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Jean-Paul Janssens, Associate Professor, Ligue Pulmonaire Genevoise
    ClinicalTrials.gov Identifier:
    NCT01608685
    Other Study ID Numbers:
    • KH-2010
    First Posted:
    May 31, 2012
    Last Update Posted:
    May 31, 2012
    Last Verified:
    May 1, 2012
    Keywords provided by Jean-Paul Janssens, Associate Professor, Ligue Pulmonaire Genevoise
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 31, 2012